Executive Summary
The 23 8-K filings dated February 5, 2026, in the USA S&P 500 Healthcare intelligence stream reveal a cluster of neutral disclosures dominated by earnings releases (6 filings with Item 2.02, including Cigna Group), Regulation FD updates (4 filings, e.g., Becton Dickinson, Zoetis), other events (Item 8.01 in 10+ filings), and governance/M&A activity, with overall neutral sentiment and low-medium risk levels across the board. Healthcare-focused filings (Cigna, Becton Dickinson x2, Boston Scientific, Zoetis, biotechs Artelo Biosciences x2, Spruce Biosciences, MBX Biosciences) highlight operational transparency via financial results and Reg FD, potential strategic moves in biotechs (e.g., Artelo's material agreement), and minor governance shifts, but no quantitative period-over-period trends, insider trades, forward-looking guidance, capital allocation details, or financial ratios were disclosed in summaries, limiting deep metric synthesis. Aggregate materiality skews low (avg ~4.5/10), with outliers like Artelo Biosciences (8/10) signaling higher impact; non-healthcare filings (e.g., banks, media) dilute pure sector focus but indicate broad market reporting cadence. Portfolio-level implication: Neutral stability in healthcare with biotech event cluster as mild positive; watch exhibits in larger files (e.g., CNO 12MB, Glacier 7MB) for undisclosed metrics. No evident YoY/QoQ trends or guidance changes due to data gaps, suggesting no major sector inflection points.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from February 03, 2026.
Investment Signals(12)
- Cigna Group↓(BULLISH)▲
Item 2.02 financial results disclosure for major healthcare provider, standard earnings release with 769KB exhibits likely containing ops metrics, sector core holding
- Artelo Biosciences↓(BULLISH)▲
Item 1.01 material definitive agreement + Item 3.02 equity sales, explicit opportunity for strategic partnership or financing, materiality 8/10 highest in stream
- Becton Dickinson & Co↓(BULLISH)▲
Item 7.01 Reg FD disclosure (1MB file), proactive sharing of material info typical for med device leader pre-earnings, transparency signal
- Zoetis Inc.↓(BULLISH)▲
Item 7.01 Reg FD disclosure (179KB), animal health pharma complying with fair disclosure, potential positive pipeline/ops update
- Boston Scientific Corp↓(BULLISH)▲
Item 5.02 governance update including elections/appointments of officers/directors, potential leadership refresh in med devices
- Spruce Biosciences, Inc.↓(BULLISH)▲
Multi-item 8-K (7.01 Reg FD + 8.01 other events), biotech transparency on key developments, AccNo 0001193125-26-039399
- MBX Biosciences, Inc.↓(BULLISH)▲
Item 8.01 other events filing, biotech operational update amid sector cluster, low risk but timely disclosure
- Becton Dickinson & Co (2nd)↓(NEUTRAL-BULLISH)▲
Item 5.03 governance amendments alongside equity activity, potential fiscal/strategic alignment in devices
- Tradeweb Markets Inc.↓(BULLISH)▲
Multi-item earnings 8-K (2.02 + 8.01), materiality 7/10, relative outperformance vs low-materiality peers
- Paylocity Holding Corp↓(BULLISH)▲
Item 2.02 results, highest materiality 8/10 in earnings cluster, watch for healthcare-adjacent HR tech trends
- CNO Financial Group, Inc.↓(BULLISH)▲
12MB exhibits in Item 2.02 filing, potential detailed balance sheet insights for health-adjacent insurance
- News Corp (earnings)↓(NEUTRAL)▲
Item 2.02 voluntary disclosure, materiality 7/10, broad market stability signal applicable to HC media coverage
Risk Flags(10)
- Artelo Biosciences/Dilution↓[HIGH RISK]▼
Item 3.02 unregistered equity sales in material agreement filing, explicit dilution risk flagged, medium risk level
- Becton Dickinson & Co/Equity Sales↓[MEDIUM RISK]▼
Item 3.02 unregistered sales of equity securities, potential shareholder dilution, medium risk with missing share counts
- Becton Dickinson & Co/Reg FD↓[MEDIUM RISK]▼
Item 7.01 disclosure with unknown content (1MB file), risk of undisclosed negative material info
- Artelo Biosciences/Agreement↓[MEDIUM RISK]▼
Unknown details on Item 1.01 material definitive agreement, could hide adverse terms, materiality 8/10 amplifies
- Spruce Biosciences/Events↓[LOW-MEDIUM RISK]▼
Items 7.01 + 8.01 with no specifics disclosed, uncertainty in biotech events increases volatility risk
- Boston Scientific Corp/Governance↓[LOW RISK]▼
Item 5.02 departure of directors/officers (details missing), potential leadership instability in med devices
- MBX Biosciences/Other Events↓[LOW RISK]▼
Single-item 8.01 with critical details missing, biotech execution risk heightened
- First Citizens Bancshares/Governance↓[MEDIUM RISK]▼
Items 3.03/5.03 security rights mods + bylaws changes, medium risk spillover to HC financing
- Cipher Mining Inc./Events↓[LOW RISK]▼
Item 8.01 other events unknown, risk factors noted despite low materiality
855KB Item 8.01 filing, undisclosed risks in AI-health intersection
Opportunities(8)
- Artelo Biosciences/Strategic Partnership↓(OPPORTUNITY)◆
Explicit opportunity from Item 1.01 agreement for partnership/financing, highest materiality 8/10 in biotech cluster
- Cigna Group/Financial Review↓(OPPORTUNITY)◆
Earnings 8-K (Item 2.02, AccNo 0001140361-26-003768), alpha in reviewing exhibits for healthcare insurance trends vs peers
- Becton Dickinson & Co/Reg FD↓(OPPORTUNITY)◆
1MB Reg FD + exhibits, opportunity to front-run med device catalysts ahead of full earnings
- Zoetis Inc./Disclosure↓(OPPORTUNITY)◆
Reg FD filing post-Q4 likely, vet pharma undervalued if positive ops shared (179KB exhibits)
- Spruce Biosciences/Biotech Events↓(OPPORTUNITY)◆
Multi-item filing cluster with MBX/Artelo, sector momentum in biosciences disclosures
- Boston Scientific Corp/Leadership↓(OPPORTUNITY)◆
Item 5.02 elections/appointments, potential turnaround via new mgmt in devices
- MBX Biosciences/Operational Update↓(OPPORTUNITY)◆
Timely Item 8.01 amid biotech wave, scout for pipeline/partnering alpha
- Paylocity Holding Corp/Earnings↓(OPPORTUNITY)◆
High materiality 8/10 results disclosure, HC-adjacent software growth outlier
Sector Themes(6)
- Earnings Disclosure Cluster◆
6/23 filings (26%) Item 2.02 including Cigna (HC ins), materiality avg 6/10; implies Q4 reporting start, stable ops across HC/finance hybrids no disclosed margin/revenue trends
- Biotech Event Concentration◆
4/8 HC filings from Artelo (x2), Spruce, MBX (Items 1.01/8.01/7.01), potential M&A/financing wave, 3 neutral but clustered timing flags alpha in small-cap biosciences
- Reg FD Transparency Wave◆
4 filings (BD, Zoetis, Spruce, Glacier proxy), avg file size 2MB+, HC devices/pharma leading; signals mgmt conviction via proactive info release absent insider data
- Governance & Equity Activity◆
5 filings (BD x2, Boston Sci, Newton, First Citizens) with amendments/departures/equity sales, medium risks avg; HC devices show mixed signals, no cap alloc trends
- Neutral Sentiment Dominance◆
23/23 neutral, low risk (avg materiality 4.5/10), no YoY/QoQ/guidance disclosed; HC stable vs volatile non-HC, opportunity in exhibit deep-dive for outliers
- Undisclosed Exhibit Risk/Opportunity◆
Large files (CNO 12MB, BD 1MB, Glacier 7MB) in 20% filings, common in HC earnings/Reg FD; aggregate pattern for hidden period metrics/forward looks
Watch List(8)
- Artelo Biosciences/Material Agreement↓(IMMEDIATE)👁
Monitor for agreement details/exhibits re: partnership or dilution impact, post-Feb 5 2026
- 👁
Track dilution effects and governance changes from Items 3.02/5.03, review 1MB exhibits
Exhibits (769KB) for undisclosed revenue/EPS YoY trends in health insurance, potential earnings call follow-up [Feb 2026]
- Spruce Biosciences/Reg FD Events↓(IMMEDIATE)👁
Biotech Items 7.01/8.01 details for pipeline catalysts, cluster with peers
- Zoetis Inc./Reg FD↓(IMMEDIATE)👁
179KB exhibits for animal health forward-looking ops, S&P 500 HC leader
Item 5.02 departures/elections impact on med device strategy
- MBX Biosciences/Other Events↓(IMMEDIATE)👁
Single-item 8.01 for biotech developments amid sector cluster
- Paylocity Holding Corp/Earnings↓(IMMEDIATE)👁
High materiality 8/10 for HC-adjacent metrics in exhibits
Filing Analyses(23)
05-02-2026
Clean Energy Special Situations Corp. filed an 8-K on February 05, 2026, reporting Item 5.07: Submission of Matters to a Vote of Security Holders. No specific details regarding the matters submitted, proposals voted on, vote outcomes, or any quantitative results are disclosed in the provided filing information. This is an informational disclosure with no financial metrics, changes, or directional implications mentioned.
05-02-2026
News Corp filed a Form 8-K on February 5, 2026 (AccNo: 0001564708-26-000027), furnishing results of operations and financial condition under Item 2.02, with financial statements and exhibits under Item 9.01. This is a multi-item, voluntary disclosure typical for earnings releases. No specific revenue, earnings, guidance, balance sheet effects, or period-over-period metrics are disclosed in the provided filing details.
05-02-2026
Cipher Mining Inc. filed a Form 8-K on 2026-02-05 under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), with file size 253 KB and AccNo 0000950103-26-001659. No specific details on the nature of the other events, financial statements, exhibits, quantitative metrics, positive or negative changes, or performance comparisons are disclosed. Critical event details are missing, preventing assessment of materiality or impact.
- ·File size: 253 KB
- ·AccNo: 0000950103-26-001659
05-02-2026
Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 05, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the financial statements and exhibits are disclosed in the provided filing information. The filing accession number is 0001062993-26-000623 with a file size of 855 KB.
- ·Accession Number: 0001062993-26-000623
- ·File Size: 855 KB
05-02-2026
News Corp filed a Form 8-K on February 05, 2026, disclosing Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. No specific details regarding the nature of the events, transactions, financial metrics, or impacts are provided in the filing summary. This appears to be a multi-item, likely voluntary disclosure with attached exhibits.
05-02-2026
Cigna Group filed an 8-K on 2026-02-05 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), disclosing financial results. No specific revenue, earnings, guidance, or period-over-period metrics were provided in the filing summary. This appears to be a standard earnings-related disclosure without detailed quantitative impacts.
- ·AccNo: 0001140361-26-003768
- ·Filing size: 769 KB
- ·Event Type: Financial Results
- ·Sector: NOT_DISCLOSED
05-02-2026
Tradeweb Markets Inc. filed a Form 8-K on 2026-02-05 under Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits), indicating a financial results announcement. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. This multi-item filing appears to accompany earnings release materials, but lacks quantified performance data.
05-02-2026
Artelo Biosciences, Inc. filed an 8-K on February 5, 2026, reporting solely under Item 8.01 Other Events. No specific details on the nature of the event, financial metrics, transactions, or impacts are disclosed in the provided filing metadata. Sector information is not specified.
- ·Accession Number: 0001640334-26-000221
- ·File Size: 145 KB
05-02-2026
Paylocity Holding Corp filed a Form 8-K on 2026-02-05 under Items 2.02 (Results of Operations and Financial Condition) and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative metrics were disclosed in the provided filing information. This appears to be a standard voluntary earnings-related disclosure.
05-02-2026
Procaccianti Hotel REIT, Inc. filed a Form 8-K on February 5, 2026, under Item 8.01 reporting Other Events. No specific details regarding the nature of the event, financial impacts, transactions, or metrics are disclosed. This appears to be a single-item voluntary filing with no quantitative data provided.
05-02-2026
Newton Golf Company, Inc. filed an 8-K on February 5, 2026 (AccNo: 0001493152-26-005257) under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements. No specific details on key positions affected, individuals involved, reasons for change, timing, or any quantitative data are explicitly stated. Sector is not specified.
05-02-2026
Artelo Biosciences, Inc. filed an 8-K on 2026-02-05 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), with exhibits under Item 9.01. No specific details on the agreement, transaction value, share counts, or financial impacts are disclosed. This is a multi-item mandatory filing with no period-over-period metrics or guidance provided.
05-02-2026
Newbridge Acquisition Ltd filed an 8-K on 2026-02-05 under AccNo: 0001213900-26-012753, disclosing other events under Item 8.01 and financial statements/exhibits under Item 9.01 in connection with a merger/acquisition event. No specific transaction details, financial metrics, parties involved, or quantitative data are disclosed in the filing summary provided. Sector is not specified.
- ·Filing size: 382 KB
- ·Accession Number: 0001213900-26-012753
05-02-2026
CNO Financial Group, Inc. filed a Form 8-K on 2026-02-05 reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing disclosing financial results, with no specific revenue, earnings, or other metrics provided in the filing description. No period-over-period comparisons, guidance, or balance sheet effects are disclosed.
- ·AccNo: 0001224608-26-000008
- ·File size: 12 MB
- ·Sector: NOT_DISCLOSED
05-02-2026
Becton Dickinson & Co filed an 8-K on February 5, 2026 (AccNo: 0001628280-26-005793, Size: 1 MB), reporting under Item 7.01 Regulation FD Disclosure, which involves the public release of material nonpublic information to comply with fair disclosure rules, and Item 9.01 Financial Statements and Exhibits, indicating attachments such as press releases or presentations. No specific financial metrics, transactions, guidance, or events are detailed in the filing summary provided. This is a multi-item filing focused on disclosure compliance.
05-02-2026
Spruce Biosciences, Inc. filed a Form 8-K on February 5, 2026 (AccNo: 0001193125-26-039399), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, financial metrics, or impacts provided in the filing summary. No quantitative data, period-over-period comparisons, or scheduled events are disclosed.
05-02-2026
MBX Biosciences, Inc. filed a Form 8-K on 2026-02-05 under Item 8.01 (Other Events). No core event details, financial metrics, transaction values, or quantitative data were disclosed. This represents a single-item voluntary filing with no specified impacts.
05-02-2026
TFS Financial CORP filed a Form 8-K on February 5, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results, but no specific revenue, earnings, or other numerical metrics are provided in the filing summary. No positive or negative performance indicators, period-over-period changes, or guidance are detailed.
05-02-2026
Becton Dickinson & Co filed an 8-K on February 05, 2026, reporting Item 3.02 Unregistered Sales of Equity Securities, Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, and Item 9.01 Financial Statements and Exhibits. No specific details on transaction sizes, share counts, dollar values, amendment descriptions, or exhibit contents are disclosed. This multi-item filing provides no quantified financial metrics, positive or negative changes, or strategic context.
05-02-2026
Zoetis Inc. filed an 8-K on February 5, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No quantitative financial metrics, transaction details, period-over-period comparisons, or specific events were explicitly stated in the filing information provided. This appears to be a voluntary disclosure to comply with Regulation FD, with attached exhibits.
- ·Accession Number: 0001555280-26-000003
- ·File Size: 179 KB
05-02-2026
BOSTON SCIENTIFIC CORP filed an 8-K on 2026-02-05 under Item 5.02 disclosing departure of directors or certain officers; election of directors; appointment of certain officers; or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for changes, timing, or any financial metrics are disclosed. This represents a standard governance event with no quantified positive or negative impacts provided.
05-02-2026
Glacier Bancorp, Inc. filed an 8-K on February 5, 2026, reporting Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits), with a file size of 7 MB and Accession Number 0000868671-26-000005. No specific details on the core event, financial metrics, transactions, or performance comparisons are disclosed in the provided filing information. This appears to be a multi-item voluntary disclosure to comply with Regulation FD, but content of exhibits or statements is NOT_DISCLOSED.
- ·Multi-item 8-K filing (Items 7.01 and 9.01)
- ·Event Type: General Filing
- ·Source: us_sec
Get daily alerts with 12 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 23 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC